Funding for this research was provided by:
Biotechnology and Biological Sciences Research Council (BB/R014949/1)
Wellcome Trust (208375/Z/17/Z)
Received: 19 October 2022
Accepted: 27 February 2023
First Online: 28 March 2023
: JPM is CSO of YouthBio Therapeutics, a company developing rejuvenation gene therapies based on partial reprogramming, an advisor/consultant for the Longevity Vision Fund and NOVOS, and the founder of Magellan Science Ltd, a company providing consulting services in longevity science.